MY191697A - Use of the pacap as a molecular adjuvant for vaccines - Google Patents

Use of the pacap as a molecular adjuvant for vaccines

Info

Publication number
MY191697A
MY191697A MYPI2014700419A MYPI2014700419A MY191697A MY 191697 A MY191697 A MY 191697A MY PI2014700419 A MYPI2014700419 A MY PI2014700419A MY PI2014700419 A MYPI2014700419 A MY PI2014700419A MY 191697 A MY191697 A MY 191697A
Authority
MY
Malaysia
Prior art keywords
pacap
vaccines
adjuvant
aquatic organisms
molecular adjuvant
Prior art date
Application number
MYPI2014700419A
Other languages
English (en)
Inventor
Maria Lugo Gonzalez Juana
Carpio Gonzalez Yamila
Pablo Estrada Garcia Mario
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of MY191697A publication Critical patent/MY191697A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2014700419A 2011-08-26 2012-08-24 Use of the pacap as a molecular adjuvant for vaccines MY191697A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2011000167A CU24075B1 (es) 2011-08-26 2011-08-26 Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
PCT/CU2012/000004 WO2013029570A1 (es) 2011-08-26 2012-08-24 Uso del pacap como adyuvante molecular para vacunas

Publications (1)

Publication Number Publication Date
MY191697A true MY191697A (en) 2022-07-07

Family

ID=47046313

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014700419A MY191697A (en) 2011-08-26 2012-08-24 Use of the pacap as a molecular adjuvant for vaccines

Country Status (19)

Country Link
US (1) US9549977B2 (ja)
EP (1) EP2749291B1 (ja)
JP (1) JP6077541B2 (ja)
KR (1) KR101857705B1 (ja)
CN (1) CN103874510A (ja)
AU (1) AU2012303887B2 (ja)
BR (1) BR112014004620B1 (ja)
CA (1) CA2844898C (ja)
CL (1) CL2014000386A1 (ja)
CU (1) CU24075B1 (ja)
ES (1) ES2648337T3 (ja)
MX (1) MX351725B (ja)
MY (1) MY191697A (ja)
NO (1) NO2749291T3 (ja)
PT (1) PT2749291T (ja)
RU (1) RU2580294C2 (ja)
SG (1) SG11201400215SA (ja)
WO (1) WO2013029570A1 (ja)
ZA (1) ZA201401271B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190060057A (ko) 2017-11-24 2019-06-03 유병희 웰빙 무드등
CN114173874A (zh) * 2019-05-14 2022-03-11 千寿制药株式会社 含pacap肽或pacap的稳定化肽的神经营养性角膜炎的预防或治疗用组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE65568B1 (en) * 1990-10-22 1995-11-01 Unilever Plc Vaccine compositions for fish
SK5552002A3 (en) * 1999-09-28 2003-05-02 Bayer Ag Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
GB0427267D0 (en) * 2004-12-13 2005-01-12 Maria Teresa De Magistris Peptide adjuvants
CU23557A1 (es) 2005-11-22 2010-07-20 Ct Ingenieria Genetica Biotech Neuropéptidos para el cultivo de organismos acuáticos
AU2010313122A1 (en) * 2009-11-02 2012-05-24 The Administrators Of The Tulane Educational Fund Analogs of pitutary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
CN103255089B (zh) * 2013-05-03 2015-08-05 中国水产科学研究院黄海水产研究所 一株强毒迟缓爱德华氏菌疫苗株及其应用

Also Published As

Publication number Publication date
CA2844898A1 (en) 2013-03-07
SG11201400215SA (en) 2014-09-26
US9549977B2 (en) 2017-01-24
RU2580294C2 (ru) 2016-04-10
JP2014524450A (ja) 2014-09-22
MX2014002214A (es) 2014-04-30
BR112014004620A2 (pt) 2017-03-21
PT2749291T (pt) 2017-11-24
KR20140064847A (ko) 2014-05-28
JP6077541B2 (ja) 2017-02-08
CN103874510A (zh) 2014-06-18
KR101857705B1 (ko) 2018-06-20
CU24075B1 (es) 2015-01-29
AU2012303887B2 (en) 2017-06-22
EP2749291B1 (en) 2017-10-18
CA2844898C (en) 2021-06-22
BR112014004620B1 (pt) 2019-10-29
WO2013029570A1 (es) 2013-03-07
US20140294889A1 (en) 2014-10-02
NO2749291T3 (ja) 2018-03-17
RU2014111465A (ru) 2015-10-10
CL2014000386A1 (es) 2014-07-11
MX351725B (es) 2017-10-25
EP2749291A1 (en) 2014-07-02
AU2012303887A1 (en) 2014-03-06
ES2648337T3 (es) 2018-01-02
ZA201401271B (en) 2015-04-29
CU20110167A7 (es) 2013-06-28

Similar Documents

Publication Publication Date Title
BRPI0920240B8 (pt) composição adjuvante
AR069882A1 (es) Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e
ECSP14013315A (es) Inhibidores de aplicación viral
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
BR112013020042A2 (pt) inibidores de vírus da hepatite c
BR112013028679A2 (pt) inibidores do vírus da hepatite c
IN2014CN00572A (ja)
PH12015501378A1 (en) Porcine parvovirus 5a, methods of use and vaccine
EA201491969A1 (ru) Иммуногенные соединения, включающие пептид gp41 вич, связанный с белком-носителем crm197
CO7461135A2 (es) Parvovirus porcino 5b, métodos de uso y vacuna
CO6361950A2 (es) Composiciones, vacunas y metodos del virus del herpes del ganado bovino -1
MY167069A (en) Antigen peptide and use thereof
MY191697A (en) Use of the pacap as a molecular adjuvant for vaccines
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques
CL2014000760A1 (es) Peptido antimicrobiano aislado y purificado de branquias de tilapia (oreochromis niloticus); acido nucleico que lo codifica; composicion que lo comprende; y su uso para el control de patogenos y como adyuvante molecular en una composicion vacunal para aumentar la respuesta inmune contra el antigeno vacunal.
WO2013084070A3 (en) Salmonella vaccine proteins
MX2014009022A (es) Virus de influenza c y vacuna.
WO2015048785A3 (en) Mosaic conserved region hiv immunogenic polypeptides
EA201401044A1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
TH151450A (th) การใช้ของ pacap ในรูปโมเลกุลสารเสริมฤทธิ์สำหรับวัคซีน
CL2013001561A1 (es) Composicion que comprende al polipeptido activador de la adenilato ciclasa de pituitaria (pacap); combinacion veterinaria que comprende al pacap y una molecula antiviral; y uso del pacap para el tratamiento de enfermedades infecciosas causadas por virus en organismos acuaticos.
MX2019005122A (es) Uso de peptido secretagogo de la hormona de crecimiento como adyuvante vacunal.